PT1007055E - Utilizacao de amifostina - Google Patents

Utilizacao de amifostina

Info

Publication number
PT1007055E
PT1007055E PT98906688T PT98906688T PT1007055E PT 1007055 E PT1007055 E PT 1007055E PT 98906688 T PT98906688 T PT 98906688T PT 98906688 T PT98906688 T PT 98906688T PT 1007055 E PT1007055 E PT 1007055E
Authority
PT
Portugal
Prior art keywords
amifostine
utilization
compounds
aminoalkyl
adverse
Prior art date
Application number
PT98906688T
Other languages
English (en)
Inventor
Martin Stogniew
Philip S Schein
Original Assignee
Medimmune Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Oncology Inc filed Critical Medimmune Oncology Inc
Publication of PT1007055E publication Critical patent/PT1007055E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Insulating Materials (AREA)
PT98906688T 1997-02-12 1998-02-11 Utilizacao de amifostina PT1007055E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/798,840 US6051563A (en) 1997-02-12 1997-02-12 Methods for the administration of amifostine and related compounds

Publications (1)

Publication Number Publication Date
PT1007055E true PT1007055E (pt) 2004-06-30

Family

ID=25174410

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98906688T PT1007055E (pt) 1997-02-12 1998-02-11 Utilizacao de amifostina

Country Status (11)

Country Link
US (3) US6051563A (pt)
EP (1) EP1007055B1 (pt)
JP (1) JP2001512447A (pt)
AT (1) ATE258797T1 (pt)
AU (1) AU750591B2 (pt)
CA (2) CA2625727A1 (pt)
DE (1) DE69821498T2 (pt)
DK (1) DK1007055T3 (pt)
ES (1) ES2216271T3 (pt)
PT (1) PT1007055E (pt)
WO (1) WO1998034622A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6573253B2 (en) * 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US6051563A (en) * 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6239119B1 (en) * 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
US6407278B2 (en) 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6384259B1 (en) * 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
ES2261399T3 (es) * 2000-04-26 2006-11-16 Oregon Health Sciences University Administracion de un compuesto quimioprotector que contiene tiol.
US7053072B2 (en) * 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US7629333B2 (en) 2002-03-29 2009-12-08 Medimmune, Llc Stable amorphous amifostine compositions and methods for the preparation and use of same
EP1809272A4 (en) * 2004-10-18 2008-01-02 Maroon Biotech Corp METHOD AND COMPOSITIONS FOR TREATING DAMAGES THROUGH FREE RADICALS
JP6163304B2 (ja) 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法
CN103336902B (zh) * 2013-06-27 2016-01-13 西安交通大学 一种基于模拟分布平衡血药浓度的药物绝对生物利用度检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892824A (en) * 1968-12-16 1975-07-01 Southern Res Inst S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates
WO1989007942A1 (en) * 1988-02-23 1989-09-08 U.S. Bioscience Method for protection from chemotherapeutic side effects
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5424471A (en) * 1992-07-31 1995-06-13 U.S. Bioscience, Inc. Crystalline amifostine compositions and methods of the preparation and use of same
CA2122342A1 (en) * 1992-09-04 1994-03-17 Hironori Kawabata Pharmaceutical composition
ATE216425T1 (de) * 1994-08-13 2002-05-15 Roche Diagnostics Gmbh Verwendung von interferon-gamma zur vermeidung der proliferation und differenzierung der primitiven hämapoietischen vorläuferzellen
US5846958A (en) * 1995-02-17 1998-12-08 U.S. Bioscience, Inc. Methods of using aminothiols to promote hematopoietic progenitor cell growth
US6051563A (en) * 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds

Also Published As

Publication number Publication date
DK1007055T3 (da) 2004-06-07
AU750591B2 (en) 2002-07-25
DE69821498T2 (de) 2004-12-02
CA2280773C (en) 2008-07-22
CA2280773A1 (en) 1998-08-13
US6127351A (en) 2000-10-03
CA2625727A1 (en) 1998-08-13
AU6184998A (en) 1998-08-26
DE69821498D1 (de) 2004-03-11
US6051563A (en) 2000-04-18
EP1007055A4 (en) 2002-05-29
WO1998034622A1 (en) 1998-08-13
JP2001512447A (ja) 2001-08-21
EP1007055B1 (en) 2004-02-04
US6218377B1 (en) 2001-04-17
ATE258797T1 (de) 2004-02-15
ES2216271T3 (es) 2004-10-16
EP1007055A1 (en) 2000-06-14

Similar Documents

Publication Publication Date Title
PT1007055E (pt) Utilizacao de amifostina
HK1245320A1 (zh) 治療缺陷α半乳糖苷酶A的藥物製劑
EP1537861A3 (en) Use of aminothiol compounds for the treatment xerostomia caused by therapeutic agents or radiation
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer&#39;s disease
YU77000A (sh) Primena peg-ifn-alfa i ribavirina za lečenje hroničnog hepatitisa c
BG106057A (en) Method of enhancing the efficacy of anti-tumour agents
PT998287E (pt) Utilizacao de levobupivacaina
ATE372774T1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
AU8239298A (en) Nucleotide-comprising composition
RS52011B (sr) Nova primena derivata taksoida
ATE225177T1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
BG104179A (en) Phanquinon administration for the treatment of the alzheimer&#39;s disease
MD990258A (en) Method of treatment of the acute viral hepatitis B
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
WO2000021506A3 (en) Pharmaceutical composition of glutathione modulators with antimony and/or arsenic for cancer therapy
AU2199901A (en) The treatment of convulsive states
TR200000728T2 (tr) Kronik hepatit C&#39; nin tedavisinde IFN-alfa ve amantadin kullanımı.
NZ298141A (en) Treating lipid metabolism disorder using TCF-II
AU5434899A (en) Cancer treatment
AU2444695A (en) Use of intravenously administered iron in the therapy of tumoral and infectious diseases
UA10754A (uk) Спосіб лікуваhhя артеріальhих гіпертеhзій різhого геhезу
UA38549A (uk) Спосіб лікування хворих з опіками очей середньої і тяжкої ступені
GEU1998399Y (en) Preparation “Pheroservit-1” for Increasing the Resistivity of Young Stock Against Anemia
UA29106A (uk) Спосіб лікування вібраційної хвороби